Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03014414
Other study ID # 37586
Secondary ID R01HL128666
Status Completed
Phase N/A
First received
Last updated
Start date March 4, 2017
Est. completion date January 27, 2022

Study information

Verified date April 2024
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

People with elevated blood pressure are at higher risk of having a heart attack or stroke than people with lower blood pressure. Losing a modest amount of weight-such as 15 or 20 pounds-can reduce the risk of having a heart attack or stroke. However, it can often be a struggle to maintain weight loss over time. This study examines whether two behavioral weight-management programs can help people maintain weight loss over time. In this study, 346 adults will be randomly assigned (like flipping a coin) to one of the 12-month programs and followed for 36 months (i.e., 3 years) to see how their body weight may change.


Description:

This randomized trial will test the efficacy and cost-effectiveness of novel modules administered prior to weight loss that are explicitly designed to enhance enjoyment of healthy lifestyle behaviors independent of any longer-term health effects, and thus escalate the proportion of individuals sustaining ≥7% weight loss over the long-term. Overweight/obese individuals with elevated blood pressure will be randomized to one of two 12-month weight-management interventions (Fun First or Weight Watchers) and followed for 36 months. For Aim 1 (Primary outcome), we will test whether Fun First is more efficacious than Weight Watchers using a mediator-intervention interaction model with sufficient a priori statistical power for the interaction effect as well as the intervention and mediator main effects. The posited mediator assesses participants' change in enjoyment for four key healthy lifestyle behaviors (healthy eating, physical activity, weighing and self-nurturing) via online survey from 0-2 months. The primary outcome is the proportion of participants who lose a clinically significant amount of initial body weight and maintain it during the trial (i.e., lose >=7% of their initial body weight from 0-12 months and gain <=5 lbs from 12-36 months), assessed on clinic scales during in-person visits at the research clinic. Secondary outcomes include the proportion of individuals sustaining ≥7% weight loss over the trial assessed by digital cellular scales in participants' homes and participants' change in systolic blood pressure over the trial assessed at the research clinic. For Aim 2 (Other pre-specified outcomes), we will test whether Fun First is more cost effective than Weight Watchers using both individual-level trial data and systems science modeling for long-term, population-level hypertension and cardiovascular disease incidence, health care and disability costs, and quality-adjusted life-years over the life course.


Recruitment information / eligibility

Status Completed
Enrollment 321
Est. completion date January 27, 2022
Est. primary completion date January 27, 2022
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria (BMI): - 27 <= BMI < 45 kg/m2 Inclusion Criteria (Elevated Blood Pressure): - Systolic blood pressure between 120-159 mmHg OR diastolic blood pressure between 80-99 mmHg. Can be on >=1 antihypertensive medications if on stable dose for past 3 months - Systolic blood pressure <120 mmHg OR diastolic blood pressure <80 mmHg, if on stable dose of >=1 antihypertensive medications for past 3 months Exclusion Criteria (Blood Pressure): - Elevated blood pressure: Systolic blood pressure >=160 mmHg OR diastolic blood pressure >=100 mmHg Exclusion Criteria (Underlying medical conditions/diseases): - Have had a heart attack, stroke, coronary heart disease, congestive heart failure, or angina - Have had coronary artery bypass surgery or cardiac catheterization such as percutaneous transluminal coronary angioplasty (PTCA), cath or stent placement - Have diabetes - Have medical contraindications to regular, unsupervised physical activity - Have moderate to severe asthma, or chronic obstructive pulmonary disorder (also called emphysema or chronic bronchitis) - Had cancer in the past 5 years (except non-melanoma skin cancer) - Currently under medical care for digestive issues, gastrointestinal distress, abdominal pain, or diarrhea - Had an organ transplant Exclusion Criteria (Medications): - Not stable on medications over the past 3 months (e.g., cholesterol, thyroid, estrogen-hormone, psychiatric) - Currently taking prescription pain medications (e.g., Vicodin, Oxycodone) Exclusion Criteria (Weight and diet related): - Have binge eating disorder or bulimic compensatory symptoms - Currently taking medication designed to lose weight - Have undergone weight-loss surgery (e.g., gastric bypass, lap band) - Have lost >10 pounds in the past 6 months - Currently in a weight-loss program (e.g., Jenny Craig) - Currently participating in any support groups that focus on weight or eating habits (e.g., Overeaters Anonymous) - Currently on a special diet for a serious health condition - Not willing to discontinue a special diet (e.g., Atkins) Exclusion Criteria (Behavioral related): - Planning to move in the next year - Currently pregnant or planning to be within the next year - Participating in another research study - No regular access to a mobile phone and Internet - Not able to speak, read, or understand English for informed consent - Not willing to be randomized - Did not complete eligibility process successfully or in a timely manner - Staff discretion or judgement - Live within Bay Area (e.g., ~1-hour commute from Stanford research center)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Fun First
Learn key enjoyable maintenance skills before losing weight
Weight Watchers
Focus on losing weight first via convenient meetings and personalized online tools

Locations

Country Name City State
United States Stanford University School of Medicine Palo Alto California

Sponsors (2)

Lead Sponsor Collaborator
Stanford University National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in self-reported enjoyment of healthy lifestyle behaviors from 0-2 months Participants will rate their enjoyment of four key healthy lifestyle behaviors (healthy eating, physical activity, weighing, self-nurturing) via online survey at 0, 2, 6, 12, 24, and 36 months [Change in enjoyment from 0-2 months is the mediator in the efficacy model] Baseline to 2 months
Other Incremental cost-effectiveness ratio (U.S. Dollars per quality-adjusted life-years) of either weight-management intervention versus no intervention Participants will self-report their work productivity, costs, and quality-of-life via online surveys [Ratio will be based on changes in productivity, costs, and quality-adjusted life-years over the life course in the simulated cost-effectiveness model, see below for three self-reported measures incorporated into model] Baseline to 36 months
Other Change in self-reported work productivity and activity from 6-36 months Participants will report their work productivity and activity using the Work Productivity and Activity Impairment Questionnaire via online survey at 6, 12, 24, and 36 months 6 to 36 months
Other Change in self-reported costs of participating in the weight-management interventions from 6-36 months Participants will rate their costs of participating in the weight-management interventions via online survey at 6, 12, 24, and 36 months 6 to 36 months
Other Change in self-reported quality of life from 0-36 months Participants will rate their quality of life using the Short Form Health Survey (SF-36) via online survey at 0, 6, 12, 24, and 36 months Baseline to 36 months
Other Change in weight in kilograms from 0-36 months, assessed by clinic scales Participants will be weighed during in-person visits at the research clinic at 0, 6, 12, 24, and 36 months Baseline to 36 months
Other Proportion of participants who lose >=5% of their initial body weight from 0-36 months, assessed by clinic scales Participants will be weighed during in-person visits at the research clinic at 0, 6, 12, 24, and 36 months Baseline to 36 months
Other Change in weight in kilograms from 0-36 months, assessed by cellular scales Participants will be asked to weigh themselves at home on study-provided digital scales at least every 3 months from 0 to 36 months. Scales transmit body weight data via cellular technology in real time Baseline to 36 months
Other Proportion of participants who lose >=5% of their initial body weight from 0-36 months, assessed by cellular scales Participants will be asked to weigh themselves at home on study-provided digital scales at least every 3 months from 0 to 36 months. Scales transmit body weight data via cellular technology in real time Baseline to 36 months
Primary Proportion of participants who lose a clinically significant amount of initial body weight AND maintain it during the trial (i.e., Lose >=7% of their initial body weight from 0-12 months AND gain <=5 lbs from 12-36 months), assessed by clinic scales Participants will be weighed during in-person visits at the research clinic at 0, 6, 12, 24, and 36 months Baseline to 36 months
Secondary Proportion of participants who lose a clinically significant amount of initial body weight AND maintain it during the trial (Lose >=7% of their initial body weight from 0-12 months AND gain <=5 lbs from 12-36 months), assessed by cellular scales Participants will be asked to weigh themselves at home on study-provided digital scales at least every 3 months from 0 to 36 months. Scales transmit body weight data via cellular technology in real time Baseline to 36 months
Secondary Change in systolic blood pressure from 0-36 months Participants will have their systolic blood pressure assessed during in-person visits at the research clinic at 0, 6, 12, 24, and 36 months Baseline to 36 months
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2